Amplia Therapeutics (ASX:ATX) is undertaking a placement, director placement and entitlement offer to raise up to $13 million, with interim data from the ACCENT trial supporting its continuation.
Amplia announces capital raise to support the completion of Phase 2a ACCENT trial
October 30, 2024 Australian Biotech
Latest Video
New Stories
-
And this is why it's very hard not to be cynical in this system because this committee gets to set its own rules
November 11, 2026 - - Latest News -
The negotiating room is getting smaller as officials narrow the scope
November 11, 2026 - - Latest News -
PBAC sets out its expectations for AI in medicines submissions
November 11, 2026 - -
And this is why it's very hard not to be cynical in this system becasue this committee gets to set its own rules
November 11, 2026 - - Latest News -
Dispatch AI Index finds routine AI use but questions over governance
November 10, 2026 - - News of the Day -
Mayne Pharma sells Salisbury business to Evaris Pharma for $55.5 million
November 10, 2026 - - Latest News -
Bristol Myers Squibb Australia riders more than double their target for Rare Cancers Australia
November 10, 2026 - - Latest News

